Prolintane (Catovit, Katovit, Promotil, Villescon) is a stimulant[2] and norepinephrine-dopamine reuptake inhibitor developed in the 1950s.[3] Being an amphetamine derivative, it is closely related in chemical structure to other drugs such as pyrovalerone, MDPV, and propylhexedrine and it has a similar mechanism of action.[4] Many cases of prolintane abuse have been reported.[5]

Under the trade-name "Katovit", prolintane was commercialized by the Spanish pharmaceutical company, FHER. Katovit was sold until 2001, and was most often used by students and workers as a stimulant to provide energy, promote alertness and concentration.[medical citation needed]

See also

References

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ Hollister LE, Gillespie HK (March–April 1970). "A new stimulant, prolintane hydrochloride, compared with dextroamphetamine in fatigued volunteers". The Journal of Clinical Pharmacology and the Journal of New Drugs. 10 (2): 103–9. doi:10.1177/009127007001000205. PMID 4392006.
  3. ^ GB Patent 807835
  4. ^ Nicholson AN, Stone BM, Jones MM (November 1980). "Wakefullness and reduced rapid eye movement sleep: studies with prolintane and pemoline". British Journal of Clinical Pharmacology. 10 (5): 465–72. doi:10.1111/j.1365-2125.1980.tb01790.x. PMC 1430138. PMID 7437258.
  5. ^ Kyle PB, Daley WP (September 2007). "Domestic abuse of the European rave drug prolintane". Journal of Analytical Toxicology. 31 (7): 415–8. doi:10.1093/jat/31.7.415. PMID 17725890.